Targeting Hypoxia-Induced Carbonic Anhydrase IX Enhances Immune-Checkpoint Blockade Locally and Systemically.
Animals
Antineoplastic Agents, Immunological
/ pharmacology
Apoptosis
Breast Neoplasms
/ drug therapy
CTLA-4 Antigen
/ antagonists & inhibitors
Carbonic Anhydrases
/ chemistry
Cell Proliferation
Drug Therapy, Combination
Enzyme Induction
Female
Gene Expression Regulation, Enzymologic
Humans
Hypoxia
/ physiopathology
Lung Neoplasms
/ drug therapy
Melanoma
/ drug therapy
Mice
Mice, Inbred C57BL
Phenylurea Compounds
/ pharmacology
Prognosis
Programmed Cell Death 1 Receptor
/ antagonists & inhibitors
Sulfonamides
/ pharmacology
Survival Rate
Tumor Cells, Cultured
Tumor Microenvironment
/ drug effects
Journal
Cancer immunology research
ISSN: 2326-6074
Titre abrégé: Cancer Immunol Res
Pays: United States
ID NLM: 101614637
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
02
11
2018
revised:
19
02
2019
accepted:
09
05
2019
pubmed:
16
5
2019
medline:
10
9
2020
entrez:
16
5
2019
Statut:
ppublish
Résumé
Treatment strategies involving immune-checkpoint blockade (ICB) have significantly improved survival for a subset of patients across a broad spectrum of advanced solid cancers. Despite this, considerable room for improving response rates remains. The tumor microenvironment (TME) is a hurdle to immune function, as the altered metabolism-related acidic microenvironment of solid tumors decreases immune activity. Here, we determined that expression of the hypoxia-induced, cell-surface pH regulatory enzyme carbonic anhydrase IX (CAIX) is associated with worse overall survival in a cohort of 449 patients with melanoma. We found that targeting CAIX with the small-molecule SLC-0111 reduced glycolytic metabolism of tumor cells and extracellular acidification, resulting in increased immune cell killing. SLC-0111 treatment in combination with immune-checkpoint inhibitors led to the sensitization of tumors to ICB, which led to an enhanced Th1 response, decreased tumor growth, and reduced metastasis. We identified that increased expression of
Identifiants
pubmed: 31088846
pii: 2326-6066.CIR-18-0657
doi: 10.1158/2326-6066.CIR-18-0657
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
CTLA-4 Antigen
0
CTLA4 protein, human
0
PDCD1 protein, human
0
Phenylurea Compounds
0
Programmed Cell Death 1 Receptor
0
SLC-0111
0
Sulfonamides
0
Carbonic Anhydrases
EC 4.2.1.1
carbonic anhydrase XII
EC 4.2.1.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1064-1078Subventions
Organisme : CIHR
ID : FDN-143318
Pays : Canada
Informations de copyright
©2019 American Association for Cancer Research.